Research Analysts Issue Forecasts for Alumis FY2024 Earnings

Alumis Inc. (NASDAQ:ALMS) – Research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Alumis in a report released on Thursday, November 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($9.75) per share for the year, up from their previous forecast of ($11.42). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.39) EPS, Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.45) EPS and FY2025 earnings at ($5.68) EPS.

Other analysts also recently issued research reports about the company. Robert W. Baird initiated coverage on Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target on the stock. Morgan Stanley started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price target for the company. Guggenheim began coverage on shares of Alumis in a research report on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price objective on the stock. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Leerink Partners began coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price objective for the company. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.83.

Alumis Trading Down 6.0 %

Shares of NASDAQ ALMS opened at $8.85 on Monday. The stock has a 50-day simple moving average of $11.22. Alumis has a 52-week low of $8.23 and a 52-week high of $13.53.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Alumis during the 3rd quarter worth about $27,000. MetLife Investment Management LLC acquired a new stake in shares of Alumis during the 3rd quarter valued at $89,000. Barclays PLC purchased a new stake in shares of Alumis during the third quarter worth $197,000. Maven Securities LTD purchased a new stake in shares of Alumis during the 2nd quarter worth about $332,000. Finally, State Street Corp bought a new stake in shares of Alumis in the 3rd quarter valued at approximately $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.